GCP
PTCT icon

GSA Capital Partners’s PTC Therapeutics PTCT Stock Holding History

GSA Capital Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,754
Closed -$817K – 2079
2025
Q4 		$817K Buy
10,754
+5,428
+102% +$394K 0.07% 482
2025
Q3 		$327K Sell
5,326
-25,656
-83% -$1.34M 0.03% 1149
2025
Q2 		$1.51M Buy
+30,982
New +$1.47M 0.11% 234
2024
Q3 		– Sell
-30,858
Closed -$944K – 1930
2024
Q2 		$944K Buy
30,858
+17,151
+125% +$556K 0.07% 545
2024
Q1 		$399K Buy
+13,707
New +$384K 0.03% 1039
2022
Q3 		– Sell
-11,002
Closed -$441K – 1797
2022
Q2 		$441K Sell
11,002
-13,162
-54% -$462K 0.07% 575
2022
Q1 		$902K Buy
+24,164
New +$931K 0.12% 217
2021
Q4 		– Sell
-17,239
Closed -$641K – 1723
2021
Q3 		$641K Buy
+17,239
New +$708K 0.07% 541
2021
Q2 		– Sell
-8,540
Closed -$404K – 1546
2021
Q1 		$404K Buy
+8,540
New +$507K 0.07% 465
2020
Q1 		– Sell
-5,914
Closed -$284K – 1455
2019
Q4 		$284K Buy
+5,914
New +$251K 0.03% 1063
2019
Q2 		– Sell
-30,832
Closed -$1.16M – 1682
2019
Q1 		$1.16M Buy
30,832
+7,632
+33% +$256K 0.12% 230
2018
Q4 		$796K Sell
23,200
-5,490
-19% -$197K 0.09% 320
2018
Q3 		$1.35M Buy
+28,690
New +$1.19M 0.07% 483
2017
Q3 		– Sell
-24,300
Closed -$445K – 1841
2017
Q2 		$445K Buy
+24,300
New +$327K 0.03% 1064
2015
Q4 		– Sell
-11,487
Closed -$307K – 1931
2015
Q3 		$307K Sell
11,487
-47,787
-81% -$2.04M 0.02% 1357
2015
Q2 		$2.85M Buy
59,274
+35,385
+148% +$2.06M 0.11% 188
2015
Q1 		$1.45M Buy
+23,889
New +$1.46M 0.06% 572

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GSA Capital Partners's PTCT Position: Q1 2026 in Review

GSA Capital Partners sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 10,754 shares — an estimated $817K sold.

GSA Capital Partners first reported a position in PTCT in Q1 2015 and held it in 17 quarters. The position peaked at $2.85M in Q2 2015. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • GSA Capital Partners reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 10,754 PTC Therapeutics shares in Q1 2026, an estimated $817K.
  • GSA Capital Partners first reported a position in PTC Therapeutics in Q1 2015 and held it in 17 quarters.
  • GSA Capital Partners's PTC Therapeutics position peaked at $2.85M in Q2 2015.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.